ArticleInternational journal of chronic obstructive pulmonary disease2025
Long-Term Effects of COVID-19 on Chronic Obstructive Pulmonary Disease.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Disentangling Shared and Differential Genetic Architectures Between COVID-19 and Other Respiratory Disorders-A Genome-Wide Multi-Omics Framework.International journal of molecular sciences · 2026Article
- Long-term health outcomes in elderly COPD patients with long COVID: a 2-year prospective cohort study.Respiratory research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Research has demonstrated that chronic obstructive pulmonary disease (COPD) is a negative prognostic factor for patients with the coronavirus disease 2019 (COVID-19). The long-term complications of COVID-19 among patients with COPD remain poorly understood due to limited studies. Methods: This retrospective study included patients with COPD who underwent regular follow-ups in a medical center between January 1, 2020, and December 31, 2022. The patients were categorized into COVID-19 and non-COVID-19 groups. Comparative analyses were conducted to assess clinical demographics, characteristics, acute exacerbations of COPD (AECOPD), and survival rates between the two groups. Subgroup analysis was performed based on inpatient and outpatient status within the COVID-19 group. Results: Of the 696 patients with COPD, 86 (12.4%) were included in the COVID-19 group, while 610 (87.6%) were included in the non-COVID-19 group. Patients in the COVID-19 group were significantly older (age: 75.0 ± 8.8 years versus 72.0 ± 9.0 years, Conclusion: Age is a significant risk factor for COVID-19 infection among patients with COPD. After COVID-19, these patients exhibit an increased frequency of severe exacerbations and a high risk of mortality. Notably, the susceptibility to severe exacerbations persists regardless of whether the patients receive inpatient or outpatient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.